IRIS
PARENTI, Carmela
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.681
EU - Europa 2.910
AS - Asia 2.072
AF - Africa 425
SA - Sud America 400
OC - Oceania 11
Continente sconosciuto - Info sul continente non disponibili 5
Totale 12.504
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.451
SG - Singapore 1.044
IT - Italia 987
CN - Cina 761
IE - Irlanda 615
UA - Ucraina 535
BR - Brasile 369
CI - Costa d'Avorio 283
CA - Canada 214
DE - Germania 185
RU - Federazione Russa 185
SN - Senegal 103
SE - Svezia 96
GB - Regno Unito 62
IN - India 51
FR - Francia 43
JP - Giappone 42
FI - Finlandia 35
KR - Corea 33
VN - Vietnam 27
BE - Belgio 25
ES - Italia 25
NL - Olanda 21
UZ - Uzbekistan 19
CH - Svizzera 17
BD - Bangladesh 16
AT - Austria 15
PL - Polonia 15
CZ - Repubblica Ceca 14
AU - Australia 10
GR - Grecia 10
IQ - Iraq 10
TR - Turchia 10
ZA - Sudafrica 10
MX - Messico 9
PK - Pakistan 9
AR - Argentina 8
HU - Ungheria 7
IR - Iran 7
LB - Libano 7
MA - Marocco 7
AE - Emirati Arabi Uniti 6
CO - Colombia 6
VE - Venezuela 6
DZ - Algeria 5
EU - Europa 5
TH - Thailandia 5
EG - Egitto 4
HK - Hong Kong 4
IL - Israele 4
KE - Kenya 4
NG - Nigeria 4
NO - Norvegia 4
SA - Arabia Saudita 4
AL - Albania 3
AZ - Azerbaigian 3
BG - Bulgaria 3
EC - Ecuador 3
ID - Indonesia 3
PE - Perù 3
TN - Tunisia 3
BB - Barbados 2
CL - Cile 2
DK - Danimarca 2
BO - Bolivia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
HR - Croazia 1
JM - Giamaica 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
LK - Sri Lanka 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PS - Palestinian Territory 1
PT - Portogallo 1
PY - Paraguay 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SL - Sierra Leone 1
SV - El Salvador 1
TT - Trinidad e Tobago 1
UY - Uruguay 1
Totale 12.504
Salva come PNG Salva come JPEG
Città #
Houston 1.018
Santa Clara 994
Chandler 794
Singapore 620
Dublin 611
Jacksonville 512
Chicago 461
Catania 310
Boardman 289
Abidjan 283
Ashburn 223
Nanjing 190
Cambridge 173
Lawrence 173
Andover 171
Toronto 156
Dakar 103
Civitanova Marche 94
Wilmington 94
San Mateo 87
Bremen 83
Des Moines 71
Nanchang 65
Council Bluffs 62
Columbus 52
Shenyang 52
The Dalles 51
Hefei 47
Saint Petersburg 46
Beijing 43
Jiaxing 42
Ottawa 42
Rome 42
Changsha 40
Munich 39
Los Angeles 38
Tianjin 38
Tokyo 35
Hebei 34
Seoul 33
São Paulo 33
Grafing 32
Naples 31
Brussels 24
Moscow 19
Turku 18
Dong Ket 17
Falls Church 17
New York 17
Pune 17
Seattle 17
Jinan 15
Ningbo 15
Norwalk 15
San Giovanni la Punta 14
Augusta 13
Helsinki 13
Messina 13
Rio de Janeiro 13
Washington 13
Belo Horizonte 11
Mascalucia 11
Zhengzhou 11
Paternò 10
Kunming 9
Leawood 9
Madrid 9
Salerno 9
Ann Arbor 8
Brooklyn 8
Campinas 8
Fremont 8
Fuzhou 8
Liberty Lake 8
Palermo 8
Tappahannock 8
Brno 7
Budapest 7
East Stroudsburg 7
Hanoi 7
Milan 7
Salvador 7
Siracusa 7
Tashkent 7
Amsterdam 6
Ardabil 6
Bologna 6
Cagliari 6
Dallas 6
Den Haag 6
Fortaleza 6
Fukuoka 6
Groningen 6
Johannesburg 6
Marseille 6
Melbourne 6
Mountain View 6
Mumbai 6
Redwood City 6
San Francisco 6
Totale 8.972
Salva come PNG Salva come JPEG
Nome #
Wilms' tumor gene 1 silencing inhibits proliferation of human osteosarcoma MG-63 cell line by cell cycle arrest and apoptosis activation. 421
Simultaneous targeting of MOR/DOR: A useful strategy for inflammatory pain modulation 380
NOP RECEPTOR ANTAGONISM IN THE VENTROLATERAL PERIAQUEDUCTAL GRAY ATTENUATES THE DEVELOPMENT OF OPIOID TOLERANCE. 301
((2S)-N-2-methoxy-2-phenylethyl-6,7-benzomorphan compound (2S-LP2): Discovery of a biased mu/delta opioid receptor agonist 213
Involvement of sigma 2 receptor on motor disorder 169
Neuroprotective effects of Rosmarinus officinalis L. extract in oxygen glucose deprivation (OGD)-injured human neural-like cells 142
Design, synthesis, in vitro evaluation, and molecular modeling studies of N-substituted benzomorphans, analogs of LP2, as novel MOR ligands 125
Influenza del N-sostituente della (–)-cis-N-Normetazocina nella modulazione del profilo funzionale al MOR, DOR e KOR: da agonista ad antagonista attraverso ligandi misti agonisti/antagonisti 120
Inhibition of Cx43 mediates protective effects on hypoxic/reoxygenated human neuroblastoma cells 115
Exploiting the Power of Stereochemistry in Drug Action: 3-[(2S,6S,11S)-8-Hydroxy-6,11-dimethyl-1,4,5,6-tetrahydro-2,6-methano-3-benzazocin-3(2H)-yl]-N-phenylpropanamide as Potent Sigma-1 Receptor Antagonist 111
Development of a Sigma-2 Receptor affinity filter through a Monte Carlo based QSAR analysis 104
Synthesis and Structure-Activity Relationships of LP1 Derivatives: N-Methyl-N-phenylethylamino Analogues as Novel MOR Agonists 99
Novel N-Substituted Benzomorphan-Based Compounds: From MOR-Agonist/DOR-Antagonist to Biased/Unbiased MOR Agonists 99
R- ed S-LP2: sintesi, molecular docking e valutazione farmacologica 96
From plant to bench: natural products as source for analgesic drug development. 96
Synthesis, in vitro and in vivo characterization of new benzoxazole and benzothiazole-based sigma receptor ligands 96
Studio aerobiologico e incidenza di pollinosi nella popolazione acese 93
(+)-and (−)-Phenazocine enantiomers: evaluation of their dual opioid agonist/σ1 antagonist properties and antinociceptive effects 93
Intercellular communication and ion channels in neuropathic pain chronicization 93
Sigma-2 receptor ligands QSAR model dataset 92
Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization 91
CHF5074 protects SH-SY5Y human neuronal-like cells from amyloidbeta 25-35 and tumor necrosis factor related apoptosis inducing ligand toxicity in vitro 90
LP2 e 2S-LP2: agonisti biased dual target MOR/DOR nel trattamento del dolore cronico 89
Development of novel LP1-based analogues with enhanced delta opioid receptor profile 87
In Vitro Antioxidant Activity and In Vivo Topical Efficacy of Lipid Nanoparticles Co-Loading Idebenone and Tocopheryl Acetate 87
The Multimodal MOPr/DOPr Agonist LP2 Reduces Allodynia in Chronic Constriction Injured Rats by Rescue of TGF-β1 Signalling 87
Connexins in the central nervous system: physiological traits and neuroprotective targets 85
Benzomorphan skeleton, a versatile scaffold for different targets: A comprehensive review 85
The benzomorphan-based LP1 ligand is a suitable MOR/DOR agonist for chronic pain treatment 83
Wilms’ Tumor Gene 1 (WT1) silencing inhibits proliferation of malignant peripheral nerve sheath tumor sNF96.2 cell line 83
ANTIALLODINIC AND ANTIHYPERALGESIC EFFECTS OF LP1, AN OPIOID MULTITARGET LIGAND, IN INFLAMMATORY AND NEUROPATHIC PAIN STATES 83
The benzomorphan-based compound LP1 is a central acting MOR agonist/DOR antagonist suitable for chronic pain treatment 82
Chronic treatment with fluoxetine induces sex-dependent analgesic effects and modulates HDAC2 and mGlu2 expression in female mice 82
The antagonistic effect of the sigma 1 receptor ligand (+)-MR200 on persistent pain induced by inflammation. 81
Effect of CCK-8 on analgesia induced by cold-restraint stress in the rat 80
Dual MOR/DOR agonist benzomorphan-based compounds for pain relief 80
Central and peripheral control by endogenous opioid peptides of gastric protection in stressed-rats 80
A new Sigma-1 Receptor antagonist in Chronic Pain Treatment: (+)-2R/S-LP2 effects in inflammatory and neuropathic pain 79
Ischemic tolerance modulates TRAIL expression and its receptors and generates a neuroprotected phenotype 78
Prevention of stress-induced gastric ulcers by mu- and delta-opioid agonists in the rat. 77
Multitarget opioid ligands in pain relief: New players in an old game 77
Antinociceptive profile of LP1, a non-peptide multitarget opioid ligand. 77
Novel Sigma-1 receptor antagonists: From opioids to small molecules: What is new? 77
Mu and Delta Opioid Receptor Targeting Reduces Connexin 43-Based Heterocellular Coupling during Neuropathic Pain 75
Neuroprotective effect of the new sigma receptor ligands cis-(+) and cis-(–)-PPCC 75
A new sigma ligand, (+/-)-PPCC, antagonizes kappa opioid receptor-mediated antinociceptive effect 75
The Benzomorphan-Based Compound LP1 as Suitable Candidate for Pain Management 75
Benzomorphan scaffold for opioid analgesics and pharmacological tools development: A comprehensive review 75
Evaluation of N-substituent structural variations in opioid receptor profile of LP1. 75
Tumor necrosis factor-related apoptosis-inducing ligand reduces the expression of the neuroprotective Na+ /Ca2+ exchanger isoform NCX3 in human neuroblastoma SH-SY5Y cells 75
Involvement of the Heme-Oxygenase Pathway in the Antiallodynic and Antihyperalgesic Activity of Harpagophytum procumbens in Rats. 74
Multitarget Opioid/Non-opioid Ligands: A Potential Approach in Pain Management 74
Repeated activation of delta opiod receptors counteracts nerve injury-induced TNF-α up-regulation in the sciatic nerve of rats with neuropathic pain: A possible correlation with delta opiod receptors-mediated antiallodinic effect. 74
Effects of dinorphin 1-13 on hyperalgesia induced by interleukin-1bera in the rat 73
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 73
Preclinical evidence of enhanced analgesic activity of duloxetine complexed with succinyl-β-cyclodextrin: A comparative study with cyclodextrin complexes 73
Wilms' tumor 1 (WT1) protein expression in human developing tissues 72
In vitro and in vivo pharmacological evaluation of LP1, a benzomorphan-based compound 72
Simultaneous Activation of Mu and Delta Opioid Receptors Reduces Allodynia and Astrocytic Connexin 43 in an Animal Model of Neuropathic Pain 72
Activity of profens as racemic (R and S) enantiomers in human condrocytes and cartilage 71
Apoptotic effects of (±) MRJF4 in prostate cancer cells 71
MOR/DOR targeting: an useful strategy in pain management 71
Effect of supraspinal Nocistatin on nociceptin/OrphaninFQ antagonism of selective opioid analgesia 70
Progress in the development of more effective and safer analgesics for pain management 70
Rosemary Essential Oil-Loaded Lipid Nanoparticles: In Vivo Topical Activity from Gel Vehicles 69
Design, synthesis, and biological evaluation of new hybrid MOR agonist/HDACi compounds: an innovative approach for persistent pain management 68
THE BENZOMORPHAN-BASED COMPOUND LP1 AS A MULTITARGET OPIOID LIGAND FOR CHRONIC PAIN TREATMENT 68
Effects of a Selective Sigma 1 Antagonist Compound on Inflammatory Pain 68
Role of the Nrf2/HO-1 axis in bronchopulmonary dysplasia and hyperoxic lung injuries 68
(+)-Mr200 derivatives: modifications on the amino moiety. In vitro and in vivo pharmacological evaluation 67
Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia 67
Scouting new sigma receptor ligands: Synthesis, pharmacological evaluation and molecular modeling of 1,3-dioxolane-based structures and derivatives 67
Rescue of noradrenergic system as a novel pharmacological strategy in the treatment of chronic pain: Focus on microglia activation 67
Stress-induced changes in the thermic effects of cholecystokinin in the rat 66
Involvement of the Nociceptin/Orphanin FQ-NOP receptor system in the ventrolateral periaqueductal gray following mechanical allodynia in chronic pain 66
The blockade of NOP receptor in the vlPAG reduces the development of tolerance to opioid-induced antinociception in rats 66
Sigma-1 Receptor Inhibition Reduces Mechanical Allodynia and Modulate Neuroinflammation in Chronic Neuropathic Pain 65
INVOLVEMENT OF ENDOGENOUS OPIOIDS IN THE ANALGESIC EFFECT OF SUBSTANCE P AT SUPRASPINAL LEVEL 64
ANTIALLODYNIC AND ANTIHYPERALGESIC EFFECTS OF INTRAPLANTAR NOCISTATIN AND (±)-J 113397 IN INFLAMMATORY PAIN 64
The multitarget opioid ligand LP1's effects in persistent pain and in primary cell neuronal cultures 64
Antiallodynic and antihyperalgesic effects of intraplantar nocistatin and (+/-)-J113397 in inflammatory pain 63
In-vitro evaluation of a new benzomorphan-based ligand 63
Synthesis and structure-activity relationships of (–)-cis-N-normetazocine-based LP1 derivatives 63
Harpagophytum procumbens extract potentiates morphine antinociception in neuropathic rats. 63
Synthesis and in vitro opioid receptor studies on benzomorphan-based compounds: LP1, a potent and long-acting antinociceptive 62
Inhibition of pain response in the formalin test by naloxone in normal- or cold-.restrained-rats 61
Involvement of prostaglandins on morphine-induced gastric protection in rats 61
An LP1 analogue, selective MOR agonist with a peculiar pharmacological profile, used to scrutiny the ligand binding domain 61
Antiallodinic and antihyperalgesic effects of LP1, an opioid multitarget ligand, in inflammatory and neurophatic pain states 61
Novel N-normetazocine Derivatives with Opioid Agonist/Sigma-1 Receptor Antagonist Profile as Potential Analgesics in Inflammatory Pain 60
Prevention of stress-induced gastric ulcers by m- and d-opioid agonists in the rat 60
HDAC and HAT inhibitors differently affect analgesia mediated by group II metabotropic glutamate receptors 60
Opioid and sigma receptor studies. New developments in the design of selective sigma ligands 60
A New LP1 analogue is used to better understand MOR ligand Binding Domain and its mechanisms of activation 60
Idebenone: Novel strategies to improve its systemic and local efficacy 60
Different in vitro activity of flurbiprofen and its enantimers on human articular cartilage 60
Discovery of first novel sigma/HDACi dual-ligands with a potent in vitro antiproliferative activity 59
Supraspinal injection of Substance P attenuates allodynia and hyperalgesia in a rat model of inflammatory pain 59
FARMACODINAMICA DEGLI ENANTIOMERI (S),(R),DEL FLURBIPROFENE E KETOPROFENE IN COLTURE DI CARTILAGINE UMANA E CONDROCITI 59
New bifunctional antioxidant/σ1 agonist ligands: preliminary chemico-physical and biological evaluation 58
Totale 8.770
Salva come PNG Salva come JPEG
Categoria #
all - tutte 44.840
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 44.840
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.069 15 92 116 34 294 35 106 8 110 16 170 73
2021/20221.382 163 178 15 38 210 16 186 56 123 23 56 318
2022/20232.419 196 127 46 291 214 378 8 439 512 45 101 62
2023/20241.265 82 218 78 62 68 286 48 76 2 33 218 94
2024/20254.093 67 747 214 236 877 480 196 188 247 322 244 275
2025/2026196 196 0 0 0 0 0 0 0 0 0 0 0
Totale 12.945